Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.660001
+0.0050 (0.76%)
Apr 15, 2026, 11:24 AM EDT - Market open
Oragenics Employees
Oragenics had 3 employees as of December 31, 2025. The number of employees decreased by 2 or -40.00% compared to the previous year.
Employees
3
Change (1Y)
-2
Growth (1Y)
-40.00%
Revenue / Employee
n/a
Profits / Employee
-$3,280,829
Market Cap
2.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 3 | -2 | -40.00% | 3 | 0 |
| Dec 31, 2024 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2023 | 5 | -1 | -16.67% | 5 | 0 |
| Dec 31, 2022 | 6 | 1 | 20.00% | 6 | 0 |
| Dec 31, 2021 | 5 | -2 | -28.57% | 5 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 36 |
| Calidi Biotherapeutics | 29 |
| BiomX | 20 |
| GeoVax Labs | 17 |
| Silexion Therapeutics | 14 |
| Azitra | 13 |
| Decoy Therapeutics | 11 |
| Enveric Biosciences | 6 |
OGEN News
- 2 days ago - Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewsWire
- 20 days ago - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewsWire
- 4 weeks ago - ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - GlobeNewsWire
- 5 weeks ago - ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - GlobeNewsWire
- 5 weeks ago - Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia - GlobeNewsWire
- 2 months ago - Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - GlobeNewsWire
- 2 months ago - Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - GlobeNewsWire
- 5 months ago - Oragenics Q3 2025 Shareholder Update - Business Wire